Our group has previously shown that increased tumor expression of IGF2 in epithelial ovarian cancer cells is associated with resistance to paclitaxel and other microtubule stabilizing drugs, and that IGF‐targeting therapy restored drug sensitivity in cell line and xenograft models of ovarian cancer 17, 36. Here, IGF1 is linked to ovarian carcinoma.